ARTICLE | Clinical News
KAI-4169: Phase II started
January 16, 2012 8:00 AM UTC
KAI began an open-label Phase II trial to evaluate IV KAI-4169 given thrice weekly for 12 weeks in about 30 hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). Ono h...